Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ROQ.LSE
- Price
- 1.80
- Stock movement up
- +- (%)
- Company name
- Roquefort Investments PLC
- Exchange
- (LSE ,
- Currency
- GBX )
- Sector
- Healthcare >Biotechnology
- Market cap
- 244.33M
- Ent value
- 244.88M
- Price/Sales
- -
- Price/Book
- 49.57
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -60.44%
- 3 year return
- -41.52%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-12
DIVIDENDS
ROQ.LSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 49.57 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 135.74M |
| EPS (TTM) | -0.01 |
| FCF per share (TTM) | -0.01 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -18.70K |
| Operating income (TTM) | -707.58K |
| Net income (TTM) | -1.54M |
| EPS (TTM) | -0.01 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 595.66K |
| Net receivables | 87.36K |
| Total current assets | 683.02K |
| Goodwill | 0.00 |
| Intangible assets | 5.34M |
| Property, plant and equipment | 0.00 |
| Total assets | 6.07M |
| Accounts payable | 135.63K |
| Short/Current long term debt | 609.70K |
| Total current liabilities | 862.75K |
| Total liabilities | 1.14M |
| Shareholder's equity | 4.93M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -1.37M |
| Capital expenditures (TTM) | 5.00 |
| Free cash flow (TTM) | -1.79M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -31.28% |
| Return on Assets | -25.38% |
| Return on Invested Capital | -27.83% |
| Cash Return on Invested Capital | -32.33% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.85 |
| Daily high | 1.94 |
| Daily low | 1.70 |
| Daily Volume | 1.33M |
| All-time high | 12.50 |
| 1y analyst estimate | - |
| Beta | -0.31 |
| EPS (TTM) | -0.01 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 24 Apr 2025 |
Downside potential
Loading...
Downside potential data
| ROQ.LSE | S&P500 | |
| Current price drop from All-time high | -85.60% | -12.89% |
| Highest price drop | -87.60% | -56.47% |
| Date of highest drop | 7 Mar 2025 | 9 Mar 2009 |
| Avg drop from high | -45.99% | -11.07% |
| Avg time to new high | 146 days | 12 days |
| Max time to new high | 826 days | 1805 days |
COMPANY DETAILS
Marketcap
244.33M
Marketcap category
Small-cap
Description
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy, toxicology studies, and orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action. The company was incorporated in 2020 and is based in London, the United Kingdom.
Employees
10
Website
Investor relations
-
SEC filings
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found